UNITED STATES OF AMERICA BEFORE THE FEDERAL TRADE COMMISSION

In the Matter of

Abbott Laboratories, a corporation; and

St. Jude Medical, Inc., a corporation.

FTC File No. 1610126

AGREEMENT CONTAINING CONSENT ORDERS

The Federal Trade Commission ("Commission"), having initiated an investigation of the proposed acquisition by Abbott Laboratories ("Abbott") of St. Jude Medical, Inc. ("St. Jude"), hereinafter referred to as Proposed Respondents, and it now appearing that Proposed Respondents are willing to enter into this Agreement Containing Consent Orders ("Consent Agreement") to divest certain assets and providing for other relief:

)

IT IS HEREBY AGREED by and between Proposed Respondeby theirduly authorized officers and attorneyes counsel for the Commission that:

- 1. Proposed Respondent Abboist a corporation organized, existing, and doing business under and by virtue of the lawshoef state of Illinois with its offices and principalplace of business 100 Abbott Park Road, Abbott Park, Illinois 600646400.
- 2. Proposed Respondent St. Jude is a corporation organized, existing and doing business under and by virtue of the laws of the State of Minnesota, with its offices and principal plae of business located at One St. Jude Medical Drive, St. Paul, Minnesota 55117.
- 3. Proposed Respondent all the jurisdictional facts set forth in the draft of the Complaint here attached
- 4. Proposed Respondent/aive:
 - a. any further procedural steps;

- b. the requirement that the Commission's Decision Order and Order to Maintain Assets, both of which are attached hereto and made a part hereof, contain a statement of findings of fact and conclusions of law;
- c. all rights to seek judicial review or otherwisectoallenge or contest the validity of the Decision and Order entered pursuant to this Consent Agreement; and
- d. any claim under the Equal Access to Justice Act.
- 5. Because there may be interim competitive hahme, Commission may issue its Complaint and the order b Maintain Assets in this matter at any time after it accepts the Consent Agreement for public comment
- 6. Not later than thirty (30) days after the date this consent Order is signed by the Proposed Respondents, Proposed Respondents shall submitialareport, pursuant to Commission Rule 2.33, 16 C.F.R. § 2.33. Proposed Respondent also submit subsequent reports every thirty (30) days thereafter until the Order becomes final, at which time the reporting obligations contained in the Order to Maintain Assets (other than the requirement to submit an initial report pursuant to this Consent Agreement) shall control. Such reports shall be signed by the Proposed Respondents and set forth in blatemanner in which the Proposed Respondents havemplied with and will comply with the Order to Maintain Assets and the Decision and OrderuclSreports will not become part of the public record unless and until the Consent Agreement and Decision and Order are accepted by the Commission for public commune
- 7. In each report described in Paragraph 6, Proposed Respondents shall provide sufficient information and documentation to enable the Commission to determine independently whether Proposed Respondents are in compliting consent Agreement and each of the Orders. All reports shall be verified by a notarized signatureor sworn statement of the Chief Executive Officer or other officer or employee of each Proposed Respondent specifically authorized to perform thisfunction, or self verified in the manner set forth in 28 U.S.C. § 1746. Section 2.41(a) of the Commission's Rules C.F.R. § 2.41 requires that an original and two(2) copies of all compliance reports be filed with the Commission. Proposed Respondent specifical report and one copy with the Secretary of the Commission, and shall send at least one (1) copy directly to the Bureau of Competition's Compliance Division.
- 8. This Consent Agreement and any compliance reports filed pursuant to this Consent Agreement, shall not become part of the public record of the proceeding unless and until it is accepted by the Commission. If this Consent Agreement is accepted by the Commission it, together with the **dufat** Complaint contemplated the by, will be placed on the public record for a period of thirty

AGREEMENT CONTAINING CONSENT ORDERS In the Matter of Abbott Laboratories and St. Jude Medical, Inc. FTC File No. 1610126

(30) days and information inespect thereto publicly released. The Commission thereafter may either withdraw its acceptance of this Consent Agreement and so notify Proposed Respondent which event it will take such action as it may consider appropriate, or issand servets Complaint (in such form as the circumstances may require) and Decision and Order, in disposition of the proceeding.

9. This Consent Agreement is for settlement purposes only and does not constitute an admission by Proposed Respon**stena**t the law has been violated as alleged in the draft

AGREEMENT CONTAINING CONSENT ORDERS In the Matter of Abbott Laboratories and St. Jude Medical, Inc. FTC File No. 1610126

- 13. By signing this Consent Agreement, Proposed Respondepresent and warnt thatthey can fulfill all the terms of and accomplish the full relief contemplated by the attached Decision and Ordernd the Order to Maintain Assets, and that all parents, subsidiaries, affiliates, and successors necessary to effect the full relief contemplated by this Consent Agreement and the attached Decision and Order and Order to Maintain Assets are parties are within the control of parties to this Consent Agreement and the attached Order to Maintain Assets.
- 14. By signing this Consent Agreement, Proposed Respondents represent and warrant that each Remedial Agreement (as defined in the Decision and Order) that has been submitted to the Commission at the time of this Consent Agreement for approval by the Commission in connection with the Commission's determination to make the Decision and Order final comports with all of the relevant requirements of the Decision and Order and requires Proposed Respondent divest all assets required to be divested pursuant to the relevant requirements of the Decision and Order.
- 15. Proposed Respondents agree that they shall interpret each Remedial Agreement in a manner that is fully consistent with all of the relevant provisions and remedial purposes of the Decision and Order.
- 16. Proposed Respondentiave read the draft of toeomplaint the Decision and Order, and the Order to Maintain Assetsintemplated hereby. Proposed Respondenstunderstand that once the Decision and Order has been issued, they will be required to file one or more repliance reports setting forth detail the manner in which they have complied, accemplying, and will comply with the Decision and Ordeand the Order to Maintain Assets.
- 17. Proposed Respondentgreeto comply with theterms of the proposed Decision and Order and the Order to Maintain Assets from the datestgeythis Consent Agreement. Proposed Respondent ther understand that theyay be liable for civil penalties in the amount provided by law for each violation of the Decision and Oder and of the Order to Maintain Assetter hey become final and effective.

AGREEMENT CONTAINING CONSENT ORDERS

In the Matter of Abbott Laboratories and St. Jude Medical, Inc. FTC File No. 1610126

Abbott Laboratories	FEDERAL TRADE COMMISSION
Chief Executive Officer Abbott Laboratories	Jordan S. Andrew Attorney Bureau of Competition
Dated:	Approved:
George S. Cary, Esq. Cleary Gottlieb Steen & Hamiltob P Counsel for Abott Laboratories	Michael R. Moiseyev Assistant Director Bureau of Competition
Dated:	Deborah L. Feinstein
St. Jude Medical, Inc.	Director Bureau of Competition
Chief Executive Officer St. Jude Medical, Inc.	
Joshua H. Soven, Esq. Gibson, Dunn & Crutcher LLP Counsel for St. Jude Medical, Inc.	